The market size of the global non-invasive prenatal testing market in the year 2021 is valued at 3.77 billion and is predicted to reach 10.54 billion by the year 2030 at an 12.33% CAGR during the forecast period.
Non-invasive prenatal testing, often known as non-invasive prenatal screening, is a method for determining the likelihood that a fetus will have genetic abnormalities. This type of screening is risk-free and remarkably successful for Down syndrome, Patau syndrome, Edwards syndrome, Turner syndrome, and other genetic conditions. By week 10 of pregnancy, little DNA fragments are detected in pregnant women's blood, which is frequently examined. Reduced fertility, high blood pressure, increased risk of miscarriage, stillbirths, and maternal mortality are just a few health problems that might arise as a mother ages. Maternal age can also increase the likelihood of genetic disorders in babies due to incorrect chromosomal division. The demand for non-invasive prenatal diagnostics is therefore anticipated to increase as maternal age and the prevalence of chromosomal disorders both rise. The market's organic revenue growth is driven by an increase in the majority of chromosomal abnormalities and increased product usage in new applications. Additionally, improvements in existing tests' chemistry, usefulness, and bioinformatics analysis are anticipated to fuel market expansion. The market for non-invasive prenatal testing is driven by older women's more significant chance of having infants with Down syndrome.
Furthermore, the rise in children with chromosomal problems and advancements in diagnostic imaging technology drives the demand for non-invasive prenatal testing. The market for non-invasive prenatal diagnostics is anticipated to benefit from expanding insurance coverage for typical and low-risk pregnancies. However, the high cost of testing and provisional diagnostic tools restricts the market's growth. Two more issues that could impede the expansion of the global non-invasive prenatal testing market are the decreased per capita healthcare spending and the inadequate test reimbursement policies.
The non-invasive prenatal testing market is segmented on method, end-use and application. Based on process, the market is segmented into ultrasound detection, biochemical screening tests, cell-free DNA in maternal plasma tests and others. Based on the end-user, the market is segmented into diagnostic laboratories, hospitals, research centres and clinics. Based on the application, the market is segmented into trisomy, microdelection syndrome and others.
The cell-free DNA in maternal plasma tests category dominated the market in 2021. Various genetic tests are increasingly used in prenatal care to forecast the likelihood of genetic abnormalities. With the advent of whole-genome sequencing, technological developments have broadened the scope of testing and made it possible to identify many more chromosomal abnormalities, including microdeletions and sex-specific ones. However, the use of ultrasound detection as a complement to the NIPT test based on cell-free DNA results in a lower market share. However, more recent technological developments and 3D-4D imaging have enhanced the test's real-time monitoring, safety, and efficacy, which is further likely to fuel the segment's expansion.
The trisomy category witnessed growth at a rapid rate.
The trisomy category dominated the market in 2021 because of increased chromosomal abnormalities. The prevalence of genetic illnesses is high in India. According to much research, trisomy 21 (down syndrome), which has a high incidence rate of 1 in 800 births and results in the birth of 32,000 children with down syndrome every year, is discovered in 1 in 166 newborns nationwide. Whole genome sequencing tests are now available, and they can identify a wide range of additional chromosomal abnormalities, including microdeletions and sex-specific ones.
The North American non-invasive prenatal testing market holds a significant regional revenue share.
The North American non-invasive prenatal testing market is expected to register the highest market share in revenue shortly. This can be attributable to several factors, including the high preterm birth rate, the developed healthcare system, and the rising maternal mortality rate. The prevalence of chromosomal abnormalities is rising, as is public awareness of the advantages of non-invasive prenatal testing. These factors are driving the market's expansion. The demand for non-invasive prenatal testing is increasing significantly due to the top firms' increased focus on diversifying their product lines, boosting the market's growth. In addition, the development of new, technologically sophisticated tests has a significant impact on the market expansion in this region. In addition, Asia Pacific is projected to grow rapidly in the global non-invasive prenatal testing market because of the expanding healthcare systems in developing nations like China and India, among others. Rising public healthcare spending and increased knowledge of non-invasive prenatal testing will be projected to boost market expansion. Additionally, non-invasive prenatal testing developments and technology improvements are anticipated to drive the market's growth during the projection period.
Key players in the non-invasive prenatal testing market are Yourgene Health, Illumina Inc., Agilent Technologies Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Laboratory Corporation of America Holdings, GE Healthcare, PerkinElmer Inc., BGI and Natera Inc.